The stem cell alopecia treatment market is set to grow at a compounded annual growth rate (CAGR) of 5.1% during the forecast period from 2025 to 2033. According to the research findings of National Institute of Health (NIH), the global prevalence rate of androgenic alopecia is 15.33% and is highly variable according to geographical region. It is highly prevalent in the Caucasian population which is reported to be a genetic anomaly. Currently the U.S.F.D.A. has approved only 2 drugs for treating alopecia which are Minoxidil and Finasteride, which have shown excellent therapeutic efficacy but is associated with severe adverse events. There is tremendous scope for stem cell technology to create regenerative medicine to address androgenic alopecia by employing human adipose tissue and umbilical cord embryonic mesenchymal stem cells.
"Increasing deregulation of KRT37 by androgens due to hormonal and nutritional imbalance drive the male pattern baldness market growth"
Male pattern baldness is reigning the indication segment for stem cell alopecia treatment market. It is the most common type of hair loss in men throughout the globe affecting 80% of the Caucasian population. As per the research citing of U.S. National Library of Medicine (NLM), more than 50% of men above the age of 50 years suffer from hair loss to some extent. The main causative agents are increasing deregulation of KRT37 by androgens owing to hormonal and nutritional imbalance in men. Female pattern baldness has garnered tremendous attention in the last decade on account of increasing socio-economic burden, depression & anxiety in women suffering with alopecia and rising technological advancement in dermatology science to address female pattern baldness issue. It has been reported to occur in women after menopause, hormonal imbalance is associated with the hair loss.
"Rising prevalence of androgenic alopecia and significant rise in specialty clinics & research institute treating alopecia drive the market growth in North America"
North America is dominating the regional segment for stem cell alopecia treatment market with a share of 35%. The major factors propelling the market growth in North America region are rising prevalence of androgenic alopecia and significant rise in specialty clinics and research institute indulged in stem cell alopecia treatment. Existence of technologically advanced dermatology segment and high disposable income further support the market growth in North America region. Europe is the second largest market accountable for 30% share owing to the increasing number of patients suffering with hair loss due to chemotherapy and radiation therapy. Strategic collaboration of academic research institute and pharmaceutical companies will provide necessary impetus to the research and development segment specializing in stem cell alopecia treatment. Asia Pacific represents 20% market share and is set to register impressive growth in the near future on account of rising prevalence of female pattern baldness and rise in per capita income.
Biopharmaceutical companies highly indulged in stem cell alopecia treatment market are APEX Biologix, Belgravia Center, Kerastem, Riken Research Institute, RepliCel, Sanford Burnham Prebys Medical Discovery Institute and University of Southern California.
Historical & Forecast Period
This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Stem Cell Alopecia Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
ATTRIBUTE | DETAILS |
---|---|
Research Period | 2023-2033 |
Base Year | 2024 |
Forecast Period | 2025-2033 |
Historical Year | 2023 |
Unit | USD Million |
Segmentation | |
Indication
| |
Region Segment (2023-2033; US$ Million)
|
Key questions answered in this report